Entrectinib for treating NTRK fusion-positive solid tumours: Final appraisal document

DRAFT guidance recommends for use within the Cancer Drugs Fund if the disease is locally advanced or metastatic or surgery could cause severe health problems and patients have not had an NTRK-inhibitor before, and they have no satisfactory treatment options.


National Institute for Health and Care Excellence